Qiagen NV  

(Public, NASDAQ:QGEN)   Watch this stock  
Find more results for peer production
27.12
+0.60 (2.26%)
Pre-market: 26.95 -0.17 (-0.63%)
Sep 28, 6:41AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.85 - 27.16
52 week 19.94 - 28.04
Open 26.21
Vol / Avg. 3,400.00/930,620.00
Mkt cap 6.45B
P/E 54.31
Div/yield     -
EPS 0.50
Shares 234.00M
Beta 0.90
Inst. own 66%
Nov 29, 2016
Qiagen NV at Piper Jaffray Healthcare Conference Add to calendar
Nov 15, 2016
Qiagen NV Analyst & Investor Day - 11:30AM EST - Add to calendar
Nov 3, 2016
Q3 2016 Qiagen NV Earnings Call Add to calendar
Nov 2, 2016
Q3 2016 Qiagen NV Earnings Release Add to calendar
Oct 26, 2016
Qiagen NV Extraordinary Shareholders Meeting - 3:00AM EDT - Add to calendar
Sep 19, 2016
Qiagen NV at Goldman Sachs & Berenberg German Conference
Sep 14, 2016
Qiagen NV at Morgan Stanley Global Healthcare Conference - Webcast
Sep 7, 2016
Qiagen NV at Goldman Sachs Medtech Conference
Aug 30, 2016
Qiagen NV at Commerzbank Sector Conference
Jul 29, 2016
Q2 2016 Qiagen NV Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 6.28% 9.90%
Operating margin 8.82% 13.72%
EBITD margin - 28.66%
Return on average assets 2.05% 2.94%
Return on average equity 3.21% 4.88%
Employees 4,600 -
CDP Score - -

Address

Hulsterweg 82
VENLO, 5912 PL
Netherlands
+31-77-3556600 (Phone)
+31-77-3208409 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Its bioinformatics solutions interpret data to provide actionable insights. Its automation platforms tie these together in molecular testing workflows-from Sample to Insight. Its Sample to Insight molecular technologies are applicable across a range of applications and customer classes through over 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. Its bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to decide on further action. It offers solutions in molecular diagnostics, applied testing, pharma and academia.

Officers and directors

Peer M. Schatz Chief Executive Officer, Managing Director
Age: 49
Bio & Compensation  - Reuters
Roland Sackers Chief Financial Officer, Managing Director
Age: 46
Bio & Compensation  - Reuters
Thomas Schweins Senior Vice President - Human Resources, Strategy & Marketing Services
Bio & Compensation  - Reuters
Dietrich Hauffe Senior Vice President - Life Sciences Business Area
Bio & Compensation  - Reuters
Douglas Liu Senior Vice President - Global Operations
Bio & Compensation  - Reuters
Helge Lubenow Senior Vice President - Molecular Diagnostics Business Area
Bio & Compensation  - Reuters
Ulrich Schriek Senior Vice President - Corporate Business Development
Bio & Compensation  - Reuters
Benedikt von Braunmuehl Senior Vice President - Global Commercial Operations
Bio & Compensation  - Reuters
Stephane Bancel Independent Supervisory Director
Age: 43
Bio & Compensation  - Reuters
Werner Brandt Independent Supervisory Director
Age: 62
Bio & Compensation  - Reuters